| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Amylin Pharmaceuticals, Inc. |
| Information provided by: | Amylin Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT00044707 |
Purpose
This is a randomized, single-blind, placebo-controlled, crossover study to examine the effect of pramlintide on the pharmacokinetics of an orally administered medication
| Condition | Intervention | Phase |
|
Diabetes Mellitus, Non-Insulin-Dependent |
Drug: Pramlintide acetate |
Phase II |
| MedlinePlus related topics: | Diabetes |
| Drug Information available for: | Pramlintide Pramlintide acetate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Single Blind, Placebo Control, Crossover Assignment, Pharmacokinetics Study |
Eligibility
| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contacts and Locations More Information
Link to study results on ClinicalStudyResults.org
|
| Study ID Numbers: | 137-154 |
| First Received: | September 3, 2002 |
| Last Updated: | December 14, 2007 |
| ClinicalTrials.gov Identifier: | NCT00044707 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
